03.20.24 -- Where Are They Now?

Gavin Samuels, M.D., found his work as an intensive care physician boring. It wasn't until he left the hospital and entered biopharma that he found his footing. Now, he's Chief Business Officer and General Partner at CinRx Pharma, where a deep pipeline of early- to late-stage candidates keeps him on his dealmaking toes. Dr. Samuels' introspective reflections on biotech dealmaking and negotiations plants this episode firmly on the Business of Biotech podcast highlight reel.

Advancements in AI and ML are revolutionizing the rare disease ecosystem. Explore how the integration of technology, innovation, and human connection can overcome barriers and improve patient outcomes.

Creating a site-centric partnership between a pharmaceutical/biopharmaceutical sponsor and a clinical trial site can ease personnel and patient burdens, driving high-quality data collection and documentation.

Access to digital solutions like in silico software products that help to decrease therapeutic time to market and get lifesaving drugs to patients faster and smarter remains a challenge in biopharma.

The FDA nitrosamine contamination guidance set deadlines of November 1, 2023, for risk assessment updates and August 1, 2025, for full NDSRI limit compliance.

CROs are being challenged by siloed project management. Uncover how these obstacles can be overcome with the right technology and approaches for more positive trial outcomes.

Learn more about the identification of CMAs, CPPs, and CQAs of drug products and how to predict their impact on a formulation and manufacturing processes.